

Delivery of siRNA therapeutics: PLGA nanoparticles approach

Jihane Matta¹, Rita Maalouf¹

¹Department of Sciences, Faculty of Natural and Applied Sciences, Notre Dame University - Louaize, Zouk Mosbeh, Lebanon Zouk Mikael

TABLE OF CONTENTS

1. Abstract
2. The History of RNA interference
 - 2.1. Introduction
 - 2.2. Origins of small non-coding RNAs and mechanism of gene silencing
3. Gene therapy
 - 3.1. Background information
 - 3.2. Non-viral gene therapy
 - 3.2.1. Direct chemical modifications
 - 3.2.2. Lipid-based vectors
 - 3.2.3. Polymer-based vectors
4. PLGA nanoparticles approach
 - 4.1. General overview
 - 4.2. Biological applications
 - 4.2.1. Cardiovascular diseases
 - 4.2.2. Cancer treatment
 - 4.2.3. Inflammatory diseases
 - 4.2.4. Other miscellaneous applications
5. Conclusion
6. Acknowledgement
7. References

1. ABSTRACT

RNA interference is currently one of the most advanced genomic tools providing promising insight to manage countless pathophysiological conditions that seemed unapproachable few years ago. Researchers across the globe have devised numerous methods in which small RNA molecules can be administered into target cells to manipulate cellular functions at the molecular level and eradicate defects that lead to pronounced phenotypes, which might sometimes be as fatal as malignant tumors. The present review provides an overview of the non-viral delivery approaches for siRNA therapeutics with an emphasis on the PLGA polymeric strategy and its use in different biological applications. Due to its versatile surface, PLGA is not only used in tissue engineering such as remodeling of

bone and cartilage, but it indeed plays a crucial role as chemical carrier for a broad range of therapeutic agents. It is greatly implicated in gene therapies and inherited genetic defects.

2. THE HISTORY OF RNA INTERFERENCE

2.1. Introduction

RNA interference (RNAi) is a conserved mechanism from yeast to humans that uses small regulatory non-coding RNAs to control the expression of genes. Over more than 1000 small RNAs are encoded in the human genome regulating approximately 60% of our genes (1, 2). The first hint to a role for RNA species in gene silencing came from the work of Napoli and Jorgensen who described in 1990 a revolutionary experiment done on

Petunia flowers, which laid the foundations for the later discovery of RNAi as a mechanism of gene silencing. Initially, the aim of their study was to overexpress chalcone synthase (CHS) to test whether or not this enzyme is rate-limiting in the biosynthesis of anthocyanin, a purple plant pigment. Unexpectedly, a portion of the transgenic flowers ended up with a white instead of a violet color. Napoli and Jorgensen hypothesized that the dual transcription of the endogenous and introduced CHS genes coordinately suppressed their expression, thus resulting in the white phenotype (3). This phenomenon, known as post-transcriptional gene silencing (PTGS), was reported shortly afterwards in *Caenorhabditis elegans*. Two simultaneous reports at that time revealed that the gene *lin-4* encodes small regulatory RNA which silence post-transcriptionally the *lin-14* gene involved in the temporal regulation of postembryonic developmental events (4, 5). These initial studies left a dilemma on the nature of this RNA-RNA interaction phenomenon and the structure of the RNA species involved. It was not until 1998 that Craig C. Mello and Andrew Z. Fire, who shared the 2006 Nobel Prize in Medicine for their discovery, were able to solve this scientific dilemma presented by the earlier studies. They showed that the double-stranded RNA (dsRNA) manifests a potent gene silencing effect that is more pronounced than that of purified single-stranded RNAs (ssRNA) of either sense, by noting a synergistic effect of sense and antisense RNA mixture (6). Later, studies in plants and *Drosophila* identified the stable RNA intermediate generated from dsRNA that was involved in silencing the target messenger RNA (mRNA). It appeared to be an interfering antisense RNA of small size. Since its discovery, RNAi proved to be a potent tool for the large scale systematic analysis of gene function in many organisms including *Arabidopsis* (7), *C. elegans* (8), *Drosophila* (9, 10), mosquitoes (11, 12), Zebrafish (13), and human cells (14) as well as several others.

RNA interference has been observed in several living organisms, from plants to

vertebrates. It has been the most extensively used reverse genetics tool to study gene function since the last decade. Its success is attributed to the evolutionary conserved pathways that regulate gene expression via small non-coding RNAs (15), the relatively simple way to generate siRNAs or dsRNA *in vitro* and their ease of use to silence genes in several organisms. Despite its success as a gene silencing tool, RNAi has also its limitations including; incomplete phenotypes due to the lack of complete silencing, off-target effects with the 3' untranslated region of genes which may be even more problematic if the design of small RNAs is based on genomic sequences of low quality (16, 17). Additionally, some non-specific RNAi effects like activation of the interferon system by siRNA have been reported in the literature (18). Despite these drawbacks, RNAi remains the most powerful functional genomic tool recently developed.

2.2. Origins of small non-coding RNAs and mechanism of gene silencing

There are three species of small non-coding RNAs involved in gene regulation which have disparate origins but their pathways converge downstream when they assemble into the RNA-induced silencing complex (RISC). These are the microRNA (miRNA), the short interfering RNA (siRNA) and PIWI-interacting RNA (piRNA). The miRNAs originate from the genome as long primary transcripts (pri-miRNA) with single or clustered double-stranded hairpins (19) that are processed by a protein complex containing the RNase III family enzyme Drosha into short ~ 65-70 nucleotide pre-miRNAs (20-22) that are transported to the cytoplasm for further processing. On the other hand, siRNAs may originate from exogenously introduced dsRNA molecules, from viral genomes or from endogenous genomic loci such as centromeres, transposons or other repetitive sequences (23). The piRNA pathway however silences transposable elements in the gonads of metazoans through PTGS and transcriptional gene silencing (TGS). However the biogenesis and processing of piRNAs remain not fully understood but shows

clear differences with the miRNA and siRNA pathways notably in being independent of Dicer (24, 25).

In the cytoplasm, pri-mRNA and long dsRNA, whether endogenous or exogenous, are diced by the endoribonuclease Dicer that contains two RNase III domains each involved in cleaving one strand of the duplex RNA (26). The resulting dsRNAs are 21-25 nucleotides in length containing 2 nucleotides overhangs at each 3' terminal end, and a phosphate group at each 5' end (27). Small dsRNAs are then loaded into the RNA-induced silencing complex (RISC) constituted of a trimolecular assembly of dicer, TAR-RNA binding protein (TRBP), and Argonaute 2 (Ago2). In *Drosophila*, there are two Ago proteins with clearly distinct functions. Typically, miRNAs are loaded on Ago1 that lacks slicing activity and functions by repressing mRNA translation. While siRNAs are loaded on Ago2 which harbors slicing activity that results in target mRNA cleavage. In humans, however all four Ago proteins seem to participate in miRNA-mediated silencing (24). RISC assembly requires two steps: loading and unwinding (28, 29). Loading to Ago2 necessitates help from Dicer and TRBP in addition to ATP. Strand selection is not random; the strand harboring the thermodynamically less stable base pairing at its 5' end will constitute the guide strand. In *Drosophila*, this thermodynamic instability is initially detected by dicer and the dsRNA-binding protein R2D2 (30). In the unwinding step Ago2 cleaves the passenger strand in a similar manner it does a target RNA. The cleaved strand is released from Ago2 to liberate the guide strand (31, 32). In case of miRNA, the strand that is loaded to the RISC is known as the miRNA and the opposing strand is the miRNA*. Finally, silencing of the target RNA may occur by endonucleolytic cleavage or by translation repression depending on the type of Ago present in the RISC and the extent of base-pairing between the guide strand (or miRNA) and the target RNA (33). Figure 1 shows a schematic representation of the siRNA, miRNA and piRNA silencing pathways.

3. GENE THERAPY

3.1. Background information

Gene therapy uses a set of approaches to deliver genetic information to a target cell in order to prevent or cure the incidence or progression of a disease. It has recently gained enormous attention as an option for therapeutic treatment of genetic or acquired diseases. siRNA-based gene therapy showed promising potential applications in many research studies. However, the development of naked siRNA-based treatment is hindered by the difficulty of its delivery into the desired cells, tissues or organs. Due to their negative charge and molecular size, siRNAs are unable to cross the lipophilic cellular membranes. In addition, they are subject to enzymatic degradation and are rapidly eliminated by the renal system. To extend their circulation time, facilitate their transfection efficiency, and enable their selective and efficient delivery, siRNAs can be carried through viral and non-viral carriers. These carriers have been extensively researched in many *ex vivo*, *in vivo* and *in vitro* applications. Both types of carriers have their advantages and disadvantages and hence, the use of one instead of the other depends on the experimental conditions and applications (34, 35). In this review, we will focus on non-viral carriers. For the targeted delivery of siRNAs using viral vectors the readers are referred to the following excellent reviews (34, 36-38).

3.2. Non-viral gene therapy

Non-viral gene delivery was developed to avoid the mentioned serious limitations related to viral gene carriers. It involves the use of physical or chemical techniques to transfer nucleic acids into cells (34, 39, 40). Although non-viral vectors have low transfection efficiency, they are much safer than viral vectors. Physical methods, such as electroporation (41, 42), microinjection (43), sonoporation (44), gene gun (45), magnetofection (46), and electric field-induced molecular vibrations (47) rely on the application of physical forces to facilitate the entrance of the desired nucleic acids into




Figure 1. Schematic representation of siRNA, miRNA and piRNA silencing pathways.

the target cell across the phospholipid bilayer. Chemical methods, on the other hand, include direct modification of the siRNA backbone, its conjugation with various molecules such as lipids, polymers, peptides, and aptamers, and siRNA encapsulation in different nanoparticles (NPs) formulations (48). All these modifications decrease the likelihood of triggering an unwanted innate immune response upon the introduction of the siRNA, lower the incidence of undesirable off-target effects, and hence improve the treatment outcomes.

3.2.1. Direct chemical modifications

Direct chemical and structural modifications conducted on the siRNAs terminals, backbone, nucleobases and sugars were found to be effective at improving their pharmacodynamics and pharmacokinetics

properties. Given that the 2' position of pentose sugars is not required for siRNA recognition as well as for RISC activity, incorporation of 2'-fluoro, 2'-O-methyl, 2'-halogen, 2'-amine or 2'-deoxy at this site showed a remarkable enhanced stability compared to wild-type siRNA (49). Moreover, locked nucleic acids (LNA) and unlocked nucleic acids (UNA) proved to be beneficial for siRNA delivery. LNA are rigid structures characterized by the presence of a methylene bridge between the 2' oxygen and the 4' carbon however UNA are highly flexible structures obtained following the cleavage of the C2'-C3' bond of the sugar ring. Although they have differing physical and chemical properties, they were able to protect the siRNA duplex from degradation, increase its stability and reduce the off-target effects (49, 50). Substitution of the phosphodiester bonds by methylphosphonate,

phosphorothioate, phosphorodithioate, and triazole linkages was also investigated in many research studies and was able to improve siRNAs target affinity and plasma half-life (51, 52).

Furthermore, tagging siRNAs with moieties such as cholesterol, peptides, polymers and aptamers lead to beneficial impact on transfection efficiency and allow targeting specific cells and organs. For example, complexation of epidermal growth factor-type 2 siRNA with polyethylenimine (PEI) increased siRNA stability and reduced subcutaneous tumor growth in a mice model (53). Likewise, Soutschek and coworkers developed chemically modified siRNAs towards apolipoprotein B (apoB) for the treatment of hypercholesterolemia. Their intravenous injection in mice exhibited a silencing effect in liver and jejunum denoted by decreased plasma levels of apoB and total cholesterol (54). Cell penetrating peptides (CPP) are a class of short peptides able to translocate across cell membranes. They are used to deliver DNA, RNA, protein molecules, nanomaterials, or pharmaceutical drugs into cells primarily *via* endocytosis. The bond between cell penetrating peptides and the cargo might be covalent or non-covalent (55). CPP-mediated siRNA delivery has been used to treat diseases such as cancer, infectious diseases, and some genetic disorders and was proved to have high transfection efficiency and low cytotoxicity (56).

Although chemical modifications and siRNA bioconjugation can somehow avoid some problems related to siRNA delivery, nanoparticles that encapsulate siRNA are better at protecting it from nucleases and immune recognition (57). Thus, delivery materials are needed, among them lipid-based and polymer-based vectors hold promising potentials for siRNA transport.

3.2.2. Lipid-based vectors

Liposomes, globular vesicles with an aqueous core surrounded by a phospholipid layer, are by far the most widely used lipid-based

vectors. They are biodegradable, biocompatible, and suitable for the delivery of hydrophilic as well as hydrophobic drugs (56). They can be cationic, anionic, or neutral. However, due to the polyanionic nature of RNAi, cationic and neutral liposomes are usually preferred as carriers. The promising *in vitro* results obtained by Halder *et al.* (2006) with focal adhesion kinase (FAK) silencing using neutral liposomes pointed out that *in vivo* delivery of FAK siRNA might be a potential novel therapeutic approach to ovarian cancer (58). Cationic liposomes, on the other hand, are slightly different. They comprise three basic components: a lipophilic tail group, a connecting linker, and a cationic hydrophilic head with one or more amine groups. The positively charged head interacts with the negative phosphate backbone of nucleic acids allowing their condensation (59-61). The structure and the physicochemical properties of each liposome component, as well as the nature of the head group can affect the transfection efficiency (62, 63). Indeed, it has been shown that variables such as the size of lipoplexes and the lipid-to-DNA ratio alter significantly the level of gene expression, in experimental set-ups as well as in the lung, heart, spleen, liver and kidneys (64, 65).

3.2.3. Polymer-based vectors

Polymer-based carriers, termed polymeric nanoparticles, have been extensively used as drug vesicles. Many are biodegradable, biocompatible and non-toxic which make them good candidates for biomedical applications. They are characterized by their high-drug loading capacity, and their ability to incorporate a broad range of therapeutic agents. The polymeric shell provides protection against enzymatic degradation and rapid renal filtration. The type and molecular weight of the polymer used as well as the drug-to-polymer ratio can affect the drug loading efficiency and release profile. They also exhibit a great potential for surface functionalization that allows improving pharmacokinetic and pharmacodynamics properties and permits targeting drug delivery and accumulation of nanoparticles at the desired site of action (66-68). Cyclodextrin,

poly-L-lysine (PLL), PEI, chitosan, dendrimers and poly (D,L-lactide-co-glycolide) (PLGA) have received a lot of attention as delivery carriers.

Dendrimers are spherical, highly symmetrical, and usually monodisperse macromolecules with hyperbranched arrays. They have a central core surrounded by concentric layers called generations. Among the many different available dendrimers, polyamidoamine (PAMAM) has gained a particular interest due to its versatile nature that allows the biological and physiochemical modifications of its end groups. It has unique features such as a nanosized, easily modifiable, cationic surface. The primary amine groups on the surfaces of the PAMAM molecules facilitate their electrostatic interaction with nucleic acids, thus forming nanoscale complexes known as “dendriplexes” (69). A recent study screened a library of surface-engineered dendrimers for structure-activity relationships regarding siRNA delivery. It was demonstrated that dendrimers modified with hydrophobic ligands such as aliphatic chains and aromatic rings, as well as functional ligands such as fluorine, bromine, boronic acid, and guanidine groups improve the efficacy of the knockdown with minimal cytotoxicity (70).

Furthermore, cationic polymers such as PLL, PEI, and chitosan have attracted the attention of many scientists due to their ability to form complexes with nucleic acids by means of stable electrostatic interactions (71, 72). Their properties such as size, surface charge, and structure are dependent on the ratio of the positive charges on cationic polymers to the number of negatively charged phosphate groups in nucleic acids. Polyethyleneimine has been examined as a potential non-viral delivery vehicle for oligonucleotides, siRNA and plasmid DNA *in vitro* and *in vivo* (73). PEI exists in different molecular weights and with degrees of branching (74). Its amino groups confer two important properties: a superior buffering capacity over a wide range of pHs and an ability to condense nucleic acids to form

positively charged complexes. The toxicity and the transfection efficiency using this compound depend on the properties of the molecule used. When PEI is more branched and has a higher molecular weight, it condenses siRNA more efficiently thus increasing the delivery efficiency but at the expense of being more toxic (75). Hence, the toxicity associated with PEI has been regulated by using low molecular weight molecules, by incorporating them into other polymeric constructs, or by modifying them to either shield the charge or transform the backbone into its biodegradable analogue (71). The complexation of PEI and siRNA demonstrated a reduction in target gene in different cellular models. Kim *et al.* demonstrated the delivery of siRNA against vascular endothelial growth factor (VEGF) through polyelectrolyte complex micelles formed by the conjugation of PEGylated siRNAs (siRNA-PEG) with PEI. These micelles showed enhanced stability compared to naked VEGF siRNA. Furthermore, they were able to silence VEGF gene expression in prostate carcinoma cells up to 96.5%. They also demonstrated a greater VEGF gene silencing effect than VEGF siRNA/PEI complexes (76).

Among all, PLGA has shown immense potential as a good delivery material for a variety of drugs including anticancer and antihypertensive agents, hormones, vaccines, as well as for macromolecules such as nucleic acids, proteins, peptides, and antibodies. PLGA, is a copolymer of poly(D,L-lactic acid) and poly(glycolic acid). It is biocompatible, biodegradable, and non-toxic. Most significantly, it has been approved for human use by the US Food and Drug administration (77). In the next section, we will mainly focus on the *in vitro* and *in vivo* biological applications of PLGA vectors for gene silencing. Some of the selected examples listed below are summarized in table 1.

4. PLGA NANOPARTICLES' APPROACH

4.1. General overview

Different mechanisms are used to synthesize PLGA. Ajioka *et al.* prepared

Table 1. Therapeutic applications of PLGA for siRNA delivery

Gene therapy drug/siRNA	Delivery system	Applications
Tissue factor siRNA	Drug-eluting stents consisting of siRNA loaded in PLGA/chitosan nanoparticles	Treat neointimal hyperplasia (96)
Intracellular adhesion molecule-1 siRNA	Drug-eluting stents consisting of siRNA loaded in PLGA coating	Avoid thrombosis after coronary stent implantation (97)
Atorvastatin+lectin-like oxidized low-density lipoprotein receptor-1 siRNA	PLGA core NPs followed by 3 consecutive layers: lipid, apolipoprotein A-I and hyaluronic acid for targeting delivery	Atherosclerosis (99)
Spermidine siRNA	PLGA nanoparticles	Vaginal mucosa (102)
Aquaporin-1 siRNA	PLGA/PVA nanoparticles	Malignant HeLa cells (103)
p53 siRNA	Lipid based NPs with PLGA or PLGA-PEG	Osteocarcinoma (104)
Paclitaxel+FAK siRNA	Hyaluronic acid - PLGA nanoparticles	Avoid resistance and inhibit tumor growth (107)
MDR1 and BCL2 siRNAs complexed with PLL	PLGA nanoparticles	Avoid resistance towards paclitaxel and cisplatin in advanced ovarian cancer (108)
P-glycoprotein siRNA+Doxorubicin	C16-S-S-PEI/PLGA nanoparticles	Avoid resistance and enhance DOX efficacy in cancerous cells (109)
TNF- α siRNA	PLGA microparticles	Treat inflammatory lung disease (111)
TNF- α or keratinocide-derived cytokine or interferon gamma-induced protein siRNAs	PLGA/PEI nanoparticles	Reduce intestinal inflammation in mice (112)
TNF- α siRNA	PLGA/PEG nanoparticles	Treat chronic inflammation sites (113)
P-glycoprotein siRNA	PLGA functionalized with peptide-binding transferrin receptor	Surpass blood-barrier membrane (114)
Transferrin siRNA	PLGA nanoparticles functionalized with enhanced green fluorescent protein – epidermal growth factor -1	Treat injured brain microvascular endothelial cells (115)
mTOR siRNA	PLGA/PEI nanoparticles	Inhibit proliferation and activate apoptosis of hypoxic pulmonary arterial smooth muscle cells (116)

high molecular weight PLGA by azeotropic dehydration, using a solution of diphenylether with L-lactic acid and glycolic acid in the presence of tin powder as a catalyst at 130°C. It typically requires 20-40 hours to obtain PLGA using this protocol. However, this reaction is hard to control and the desired product has to be purified from many other by-products (78). To prepare PLGA in a shorter time, the cationic ring-opening polymerization of cyclic dimers, glycolide and lactide, is performed. Since lactide exists in two enantiomeric isomers, the synthesized PLGA polymer can be under the form of D-, L-, or D, L- stereoisomer. This

reaction requires 2-6 hours and is commonly done in the presence of stannous octoate as catalyst at 175°C. During its synthesis, fine-tuning of relevant parameters such as molecular weight, lactide to glycolide ratio, and lactide stereoisomeric composition (L- or D, L-lactide) is one of the key components for acquiring the appropriate and specific properties needed for various applications. Therefore, PLGA solubility, crystallinity, thermal stability, mechanical properties, and degradation can be controlled widening its performance spectrum (79, 80). Due to these characteristics, PLGA have found a broad range of applications

in tissue engineering including blood vessel replacement, bone, cartilage and ligament restoration as well as skin healing (81-88). Furthermore, PLGA nanoparticles have been demonstrated as a promising drug delivery platform owing to the aforementioned properties, along with their ability to sustain optimal therapeutic doses for a prolonged time. They have been used for diagnosis, vaccine delivery, and for the treatment of many pathophysiological diseases carrying a variety of drugs, as well as, antibiotics, proteins, and nucleic acids (89-91). PLGA nanoparticles' cells uptake involves an endocytic pathway. However, the major drawback is their low intracellular retention due the fast exocytosis. Surface functionalization and complexation with ligands can reduce this occurrence, enhance cellular uptake and permit targeted drug-delivery (92). For instance, nanoparticles conjugated with transferrin ligands showed increased cellular uptake and accumulation in cell populations filled with transferrin receptors. It was demonstrated that only 50% of transferrin-conjugated nanoparticles exhibit exocytosis vs. 75% of the unconjugated nanoparticles. This is mainly related to different endocytic pathways involved in their internalization (93).

4.2. Biological applications

4.2.1. Cardiovascular diseases

A recent report from the American Heart Association estimated that 92.1 million American adults are living with some form of cardiovascular disease. Coronary heart disease is the leading cause of deaths in the US (43.8%), followed by stroke (16.8%), high blood pressure (9.4%) and heart failure (9%) (94). PLGA have found many applications in cardiology, in particular as scaffolds and coating matrices for drug-eluting stents, which have been proven to be highly effective in reducing stent thrombosis and restenosis (95). Qiu *et al.* prepared a novel external stent by deposition of hybrid fibrous membranes consisting of tissue factor siRNA loaded in PLGA/chitosan nanoparticles. These siRNA eluting stents were able to attenuate neointima hyperplasia in rat vein grafts (96). In another

study, siRNAs against intracellular adhesion molecule-1 (ICAM-1) were incorporated into different PLGA resomers. These coatings proved to have no cytotoxic effect towards human umbilical vein cell line and a good hemocompatibility since no reduction in the number of platelets, leukocytes, lymphocytes, monocytes, and granulocytes was noticed after 1 h incubation. ICAM-1 siRNAs loaded in the PLGA Resomer[®] RG 752 H (75:25, acid terminated, 4,000–15,000 Da) exhibited optimal results with 95% transfection efficiency and 36% knockdown effect. These findings prove the potential incorporation of siICAM-1 in PLGA coatings for the elaboration of novel drug eluting stents (97). Cohen-Sacks and coworkers showed that platelet-derived growth factor beta-receptor antisense loaded PLGA nanoparticles could serve as effective gene delivery system for the treatment of restenosis. The synthesized nanoparticles displayed a homogenous size, high encapsulation efficiency and a sustained release (98). Dual targeting approach has been greatly reported for enhanced drug delivery and synergistic effect. In a recent study, Zhao *et al.* prepared dual-targeting bifunctional core-shell nanoparticles to deliver atorvastatin and siRNA against lectin-like oxidized low-density lipoprotein receptor-1 to endothelial cells and macrophages in the atherosclerotic lesions. The drugs were encapsulated within the first PLGA core shell followed by three consecutive layers made up from lipid for cholesterol receiving, apolipoprotein A-I for macrophage targeting and hyaluronic acid for endothelial cell targeting. These nanoparticles showed enhanced delivery and improved anti-atherosclerotic efficacy (99).

4.2.2. Cancer treatment

According to the national institute of cancer, cancer is a set of malignant diseases characterized by uncontrolled proliferation of mutated cells in a body tissue that has been exposed to mutagens. In 2012, there were 14.1 million new cases and this number is expected to rise to 23.6 million per year by 2030 (100). Several treatment options such as chemotherapy, radiotherapy, surgery and gene

therapy have been used so far but each has its implications on patients. Targeting efficiently cancerous cells, while sparing normal cells from the adverse effects of the delivered chemicals and genes, remain a challenging goal. Numerous targeted nanoparticle approaches are currently being investigated to deliver the appropriate drugs or genes into the malignant cells by mean of ligand-based targeting mechanisms. For that purpose, nanoparticles must undergo some modifications to allow their efficient delivery into the abnormal cells. This can be done using hydrophilic surfaces, coatings with a positive charge carrier and/or with proper markers to improve cellular incorporation, increase their circulation duration, and permit the differentiation between normal and cancerous cells (101). PLGA nanoparticles have attracted extensive interest for applications in cancer therapy. Woodrow *et al.* reported the efficient and sustained gene silencing of siRNA-spermidine loaded PLGA nanoparticles for the treatment of vaginal mucosa (102). Another study reported the use of siRNA-chitosan complex, encapsulated into a multilayer shell of PLGA and poly (vinyl alcohol) (PVA) for silencing Aquaporin-1 in cancer cells. These nanoparticles demonstrated high stability under physiological conditions. They reduced the expression of Aquaporin-1 by 70%, and showed no cytotoxicity up to 72 hours of incubation (103). Kundu and coworkers reported the use of lipid based NPs with either PLGA or PLGA-PEG to encapsulate p53 siRNA against osteocarcinoma. Incorporation of 10% PLGA showed the highest p53 knockdown efficiency (104).

Despite all the efforts, drug resistance remains a major challenge in the treatment of cancer. It can occur by different mechanisms, including decreased drug uptake, increased drug efflux, activation of DNA repair mechanisms, suppression of drug-induced apoptosis, etc (105). It has been shown that overexpression of FAK plays a major key role in ovarian cancer and promotes chemoresistance (106). Byeon *et al.* suggested the development of hyaluronic acid-PLGA nanoparticles encapsulating

both paclitaxel and FAK-siRNA to reverse chemoresistance. This combination therapy proved to be effective in inhibiting tumor growth in patient-derived xenograft model compared with paclitaxel alone (107). However, other researchers showed optimal suppression of chemoresistance when siRNAs loaded PLGA nanoparticles are administrated 1 day earlier than drugs. Therefore, they designed PLGA nanoparticles to co-deliver MDR1 and BCL2 siRNA aimed for the simultaneous inhibition of drug reflux and cell death defense pathways and to avoid resistance towards paclitaxel and cisplatin in recurrent or advanced ovarian cancer. To ensure high encapsulation efficiency, siRNAs were complexed with the cationic poly-L-lysine (108). Furthermore, Wu *et al.* reported the elaboration of programmable PLGA biomaterials for dynamic and consecutive release of siRNA followed by the drug. In this work, o-nitrobenzyl ester derivative caged doxorubicin (DOX) was encapsulated in polymeric NPs constructed by the self-assembly of C₁₆-S-S-PEI and PLGA. siRNA of P-glycoprotein (P-gp) were adsorbed onto its cationic polymer shell and their release were triggered by the reductive cleavage of the disulfide bond in the presence of high levels of glutathione in cancer cells. DOX is afterwards released upon irradiation and its conversion DOX prodrug into hydrophilic active DOX. This sequential release strategy showed enhanced efficacy of DOX following P-gp silencing and can be used against multiple drug resistance (109).

4.2.3. Inflammatory diseases

Inflammation occurs when tissues are injured by bacteria, trauma, toxins, heat, or any other cause. It is a defense mechanism in the body and an essential component of many illnesses including rheumatoid arthritis, sepsis, lung and gastrointestinal diseases, etc. Tumor necrosis factor- α (TNF- α) might be considered as potential therapeutic target due to its high levels in many acute and chronic inflammations. It was shown that PLGA nanoparticles loaded with TNF- α siRNA have a significant effect in decreasing the paw scores and joints effusion in a murine arthritis model (110).

Furthermore, Kelly *et al.* used anti-TNF- α siRNA encapsulated in PLGA microparticles for the treatment of inflammatory lung disease. This work revealed a sustained siRNA knockdown of TNF- α in primary monocytes for up to 72 hours (111). In another study, siRNA against TNF- α , keratinocyte-derived cytokine or interferon gamma-induced protein were adsorbed to the surface of a calcium phosphate core, followed by their encapsulation into PLGA nanoparticles coated with an outer layer of PEI to enhance cellular uptake and subsequent endosomal escape. Intrarectal application of these nanoparticles demonstrated a significant decrease of the target gene with a subsequent reduction of intestinal inflammation in mice (112). Aldayel and coworkers reported the elaboration of TNF- α siRNA loaded PLGA NPs by the double-emulsion method using a special emulsifying agent which renders the nanoparticles PEGylated and the PEGylation readily sheddable in low pH environment such as that in chronic inflammation sites. This technique showed a higher accumulation of nanoparticles in inflamed mouse foot compared to nanoparticles prepared by an acid-insensitive emulsifying agent (113).

4.2.4. Other miscellaneous applications

siRNA loaded PLGA nanoparticles have attracted a lot of interest in many other biomedical applications. They have been used to enhance drug delivery to human brain endothelial cells for future medical therapeutic prospects aiming to surpass the blood-brain barrier and overcome central nervous system disorders. PLGA nanoparticles were loaded with siRNA against P-gp, a drug efflux transporter, and were functionalized with a peptide-binding transferrin receptor. They demonstrated no cytotoxicity and a 4-fold increased efficiency compared to non-functionalized NPs (114). In another study, Chen *et al.* reported the delivery of transferrin-siRNA loaded PLGA NPs to injured brain microvascular endothelial cells. These nanoparticles showed very low cytotoxic effect and good transfection efficiency mainly due to their functionalization with enhanced green fluorescent protein – epidermal growth

factor -1 that targets the overexpressed tissue factor in the injured cells (115). Moreover, mTOR siRNA was loaded into hybrid NPs made from PEI and PLGA. They inhibited proliferation and activated apoptosis of hypoxic pulmonary arterial smooth muscle cells (116).

5. CONCLUSION

Due to the rapid progress in the applications of RNAi, it is considered as one of the most powerful tools for gene therapy. First described in 1990, it now opens endless possibilities and provides a promising insight to manage countless pathophysiological conditions that seemed inaccessible few years ago. Scientists across the globe have devised numerous methods in which small RNA molecules can be administered into target cells to manipulate cellular functions at the molecular level and eradicate defects that lead to pronounced phenotypes, which might sometimes be as fatal as malignant tumors. Targeted delivery of these RNA molecules, the action of which relies on the RNAi and subsequent gene silencing, can be done using viral or non-viral vectors. PLGA is one of the chemicals that have been approved by the FDA for use in humans. This huge medical leap is extended beyond its initial aim. Hence, it is no longer only used in tissue engineering such as remodeling of bone and cartilage, but it indeed plays a crucial role now as chemical carrier for a broad range of therapeutic agents. It is greatly implicated in gene therapies and inherited genetic defects. This field, as interesting and promising as it seems, is still in its neonatal stages. Investigations are being done in collaboration with physiologists, biomedical engineers, medical doctors, biochemists, and specialists from all scientific disciplines to adopt this modern approach and improve it, invest it optimally to yield the best results, and subsequently achieve what sounded once far-fetched.

6. ACKNOWLEDGEMENT

This work is supported by the National Council for Scientific Research (CNRS) of Lebanon.

7. REFERENCES

1. R. C. Friedman, K. K. Farh, C. B. Burge and D. P. Bartel: Most mammalian mRNAs are conserved targets of microRNAs. *Genome Res*, 19(1), 92-105 (2009)
DOI: 10.1101/gr.082701.108
2. A. Kozomara and S. Griffiths-Jones: miRBase: annotating high confidence microRNAs using deep sequencing data. *Nucleic Acids Res*, 42(Database issue), D68-73 (2014)
DOI: 10.1093/nar/gkt1181
3. C. Napoli, C. Lemieux and R. Jorgensen: Introduction of a Chimeric Chalcone Synthase Gene into Petunia Results in Reversible Co-Suppression of Homologous Genes in trans. *Plant Cell*, 2(4), 279-289 (1990)
DOI: 10.1105/tpc.2.4.2.79
4. R. C. Lee, R. L. Feinbaum and V. Ambros: The *C. elegans* heterochronic gene *lin-4* encodes small RNAs with antisense complementarity to *lin-14*. *Cell*, 75(5), 843-54 (1993)
DOI: 10.1016/0092-8674(93)90529-Y
5. B. Wightman, I. Ha and G. Ruvkun: Posttranscriptional regulation of the heterochronic gene *lin-14* by *lin-4* mediates temporal pattern formation in *C. elegans*. *Cell*, 75(5), 855-62 (1993)
DOI: 10.1016/0092-8674(93)90530-4
6. A. Fire, S. Xu, M. K. Montgomery, S. A. Kostas, S. E. Driver and C. C. Mello: Potent and specific genetic interference by double-stranded RNA in *Caenorhabditis elegans*. *Nature*, 391(6669), 806-11 (1998)
DOI: 10.1038/35888
7. P. Hilson, J. Allemeersch, T. Altmann, S. Aubourg, A. Avon, J. Beynon, R. P. Bhalerao, F. Bitton, M. Caboche, B. Cannoot, V. Chardakov, C. Cognet-Holliger, V. Colot, M. Crowe, C. Darimont, S. Durinck, H. Eickhoff, A. F. de Longevialle, E. E. Farmer, M. Grant, M. T. Kuiper, H. Lehrach, C. Leon, A. Leyva, J. Lundeberg, C. Lurin, Y. Moreau, W. Nietfeld, J. Paz-Ares, P. Reymond, P. Rouze, G. Sandberg, M. D. Segura, C. Serizet, A. Tabrett, L. Taconnat, V. Thareau, P. Van Hummelen, S. Vercruysse, M. Vuylsteke, M. Weingartner, P. J. Weisbeek, V. Wirta, F. R. Wittink, M. Zabeau and I. Small: Versatile gene-specific sequence tags for Arabidopsis functional genomics: transcript profiling and reverse genetics applications. *Genome Res*, 14(10B), 2176-89 (2004)
DOI: 10.1101/gr.2544504
8. A. G. Fraser, R. S. Kamath, P. Zipperlen, M. Martinez-Campos, M. Sohrmann and J. Ahringer: Functional genomic analysis of *C. elegans* chromosome I by systematic RNA interference. *Nature*, 408(6810), 325-30 (2000)
DOI: 10.1038/35042517
9. M. Boutros, A. A. Kiger, S. Armknecht, K. Kerr, M. Hild, B. Koch, S. A. Haas, R. Paro, N. Perrimon and C. Heidelberg Fly Array: Genome-wide RNAi analysis of growth and viability in *Drosophila* cells. *Science*, 303(5659), 832-5 (2004)
DOI: 10.1126/science.1091266
10. L. Lum, S. Yao, B. Mozer, A. Rovescalli, D. Von Kessler, M. Nirenberg and P. A. Beachy: Identification of Hedgehog pathway components by RNAi in *Drosophila* cultured cells. *Science*, 299(5615), 2039-45 (2003)
DOI: 10.1126/science.1081403
11. S. Blandin, L. F. Moita, T. Kocher, M. Wilm, F. C. Kafatos and E. A. Levashina: Reverse genetics in the mosquito *Anopheles gambiae*: targeted disruption of the Defensin gene. *EMBO Rep*, 3(9), 852-6 (2002)
DOI: 10.1093/embo-reports/kvf180
12. L. F. Moita, R. Wang-Sattler, K. Michel, T. Zimmermann, S. Blandin, E. A. Levashina and F. C. Kafatos: *In vivo* identification of novel regulators and conserved pathways of phagocytosis in *A. gambiae*. *Immunity*,

- 23(1), 65-73 (2005)
DOI: 10.1016/j.immuni.2005.05.006
13. A. Dodd, S. P. Chambers and D. R. Love: Short interfering RNA-mediated gene targeting in the zebrafish. *FEBS Lett*, 561(1-3), 89-93 (2004)
DOI: 10.1016/S0014-5793(04)00129-2
 14. K. Berns, E. M. Hijmans, J. Mullenders, T. R. Brummelkamp, A. Velds, M. Heimerikx, R. M. Kerkhoven, M. Madiredjo, W. Nijkamp, B. Weigelt, R. Agami, W. Ge, G. Cavet, P. S. Linsley, R. L. Beijersbergen and R. Bernards: A large-scale RNAi screen in human cells identifies new components of the p53 pathway. *Nature*, 428(6981), 431-7 (2004)
DOI: 10.1038/nature02371
 15. R. C. Wilson and J. A. Doudna: Molecular mechanisms of RNA interference. *Annu Rev Biophys*, 42, 217-39 (2013)
DOI: 10.1146/annurev-biophys-083012-130404
 16. M. Boettcher and M. T. McManus: Choosing the Right Tool for the Job: RNAi, TALEN, or CRISPR. *Mol Cell*, 58(4), 575-85 (2015)
DOI: 10.1016/j.molcel.2015.04.028
 17. S. Sharma and A. Rao: RNAi screening: tips and techniques. *Nat Immunol*, 10(8), 799-804 (2009)
DOI: 10.1038/ni0809-799
 18. C. A. Sledz, M. Holko, M. J. de Veer, R. H. Silverman and B. R. Williams: Activation of the interferon system by short-interfering RNAs. *Nat Cell Biol*, 5(9), 834-9 (2003)
DOI: 10.1038/ncb1038
 19. B. R. Cullen: Transcription and processing of human microRNA precursors. *Mol Cell*, 16(6), 861-5 (2004)
DOI: 10.1016/j.molcel.2004.12.002
 20. R. I. Gregory, K. P. Yan, G. Amuthan, T. Chendrimada, B. Doratotaj, N. Cooch and R. Shiekhattar: The Microprocessor complex mediates the genesis of microRNAs. *Nature*, 432(7014), 235-40 (2004)
DOI: 10.1038/nature03120
 21. J. Han, Y. Lee, K. H. Yeom, Y. K. Kim, H. Jin and V. N. Kim: The Drosha-DGCR8 complex in primary microRNA processing. *Genes Dev*, 18(24), 3016-27 (2004)
DOI: 10.1101/gad.1262504
 22. Y. Lee, C. Ahn, J. Han, H. Choi, J. Kim, J. Yim, J. Lee, P. Provost, O. Radmark, S. Kim and V. N. Kim: The nuclear RNase III Drosha initiates microRNA processing. *Nature*, 425(6956), 415-9 (2003)
DOI: 10.1038/nature01957
 23. R. W. Carthew and E. J. Sontheimer: Origins and Mechanisms of miRNAs and siRNAs. *Cell*, 136(4), 642-55 (2009)
DOI: 10.1016/j.cell.2009.01.035
 24. J. J. Ipsaro and L. Joshua-Tor: From guide to target: molecular insights into eukaryotic RNA-interference machinery. *Nat Struct Mol Biol*, 22(1), 20-8 (2015)
DOI: 10.1038/nsmb.2931
 25. A. Le Thomas, K. F. Toth and A. A. Aravin: To be or not to be a piRNA: genomic origin and processing of piRNAs. *Genome Biol*, 15(1), 204 (2014)
DOI: 10.1186/gb4154
 26. H. Zhang, F. A. Kolb, L. Jaskiewicz, E. Westhof and W. Filipowicz: Single processing center models for human Dicer and bacterial RNase III. *Cell*, 118(1), 57-68 (2004)
DOI: 10.1016/j.cell.2004.06.017
 27. D. S. Schwarz, G. Hutvagner, T. Du, Z. Xu, N. Aronin and P. D. Zamore: Asymmetry in the assembly of the RNAi enzyme complex. *Cell*, 115(2), 199-208 (2003)
DOI: 10.1016/S0092-8674(03)00759-1
 28. T. Kawamata and Y. Tomari: Making RISC. *Trends Biochem Sci*, 35(7), 368-76 (2010)
DOI: 10.1016/j.tibs.2010.03.009
 29. H. Kobayashi and Y. Tomari: RISC assembly: Coordination between small RNAs and Argonaute proteins. *Biochim Biophys Acta*, 1859(1), 71-81 (2016)
DOI: 10.1016/j.bbagr.2015.08.007
 30. Y. Tomari, C. Matranga, B. Haley, N. Martinez and P. D. Zamore: A protein

- sensor for siRNA asymmetry. *Science*, 306(5700), 1377-80 (2004)
DOI: 10.1126/science.1102755
31. P. J. Leuschner, S. L. Ameres, S. Kueng and J. Martinez: Cleavage of the siRNA passenger strand during RISC assembly in human cells. *EMBO Rep*, 7(3), 314-20 (2006)
DOI: 10.1038/sj.embor.7400637
 32. T. A. Rand, S. Petersen, F. Du and X. Wang: Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation. *Cell*, 123(4), 621-9 (2005)
DOI: 10.1016/j.cell.2005.10.020
 33. A. van den Berg, J. Mols and J. Han: RISC-target interaction: cleavage and translational suppression. *Biochim Biophys Acta*, 1779(11), 668-77 (2008)
DOI: 10.1016/j.bbagr.2008.07.005
 34. N. Nayerossadat, T. Maedeh and P. A. Ali: Viral and nonviral delivery systems for gene delivery. *Adv Biomed Res*, 1, 27 (2012)
DOI: 10.4103/2277-9175.98152
 35. K. Gavrillov and W. M. Saltzman: Therapeutic siRNA: principles, challenges, and strategies. *Yale J Biol Med*, 85(2), 187-200 (2012)
 36. M. A. Kay, J. C. Glorioso and L. Naldini: Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. *Nat Med*, 7(1), 33-40 (2001)
DOI: 10.1038/83324
 37. L. B. Couto and K. A. High: Viral vector-mediated RNA interference. *Curr Opin Pharmacol*, 10(5), 534-42 (2010)
DOI: 10.1016/j.coph.2010.06.007
 38. J. W. Schott, M. Morgan, M. Galla and A. Schambach: Viral and Synthetic RNA Vector Technologies and Applications. *Mol Ther*, 24(9), 1513-27 (2016)
DOI: 10.1038/mt.2016.143
 39. M. S. Al-Dosari and X. Gao: Nonviral gene delivery: principle, limitations, and recent progress. *AAPS J*, 11(4), 671-81 (2009)
DOI: 10.1208/s12248-009-9143-y
 40. A. J. Mellott, M. L. Forrest and M. S. Detamore: Physical non-viral gene delivery methods for tissue engineering. *Ann Biomed Eng*, 41(3), 446-68 (2013)
DOI: 10.1007/s10439-012-0678-1
 41. J. W. Henshaw and F. Yuan: Field distribution and DNA transport in solid tumors during electric field-mediated gene delivery. *J Pharm Sci*, 97(2), 691-711 (2008)
DOI: 10.1002/jps.21000
 42. E. Neumann, M. Schaefer-Ridder, Y. Wang and P. H. Hofschneider: Gene transfer into mouse lymphoma cells by electroporation in high electric fields. *EMBO J*, 1(7), 841-5 (1982)
DOI: 10.1002/j.1460-2075.1982.tb01257.x
 43. J. K. Cinkompumin and R. L. Hong: RNAi mediated gene knockdown and transgenesis by microinjection in the necromenic Nematode *Pristionchus pacificus*. *J Vis Exp*(56), e3270 (2011)
DOI: 10.3791/3270
 44. M. Postema and O. H. Gilja: Ultrasound-directed drug delivery. *Curr Pharm Biotechnol*, 8(6), 355-61 (2007)
DOI: 10.2174/138920107783018453
 45. N. S. Yang, J. Burkholder, B. Roberts, B. Martinell and D. McCabe: *In vivo* and *in vitro* gene transfer to mammalian somatic cells by particle bombardment. *Proc Natl Acad Sci U S A*, 87(24), 9568-72 (1990)
DOI: 10.1073/pnas.87.24.9568
 46. F. Scherer, M. Anton, U. Schillinger, J. Henke, C. Bergemann, A. Kruger, B. Gansbacher and C. Plank: Magnetofection: enhancing and targeting gene delivery by magnetic force *in vitro* and *in vivo*. *Gene Ther*, 9(2), 102-9 (2002)
DOI: 10.1038/sj.gt.3301624
 47. L. Song, L. Chau, Y. Sakamoto, J. Nakashima, M. Koide and R. S. Tuan: Electric field-induced molecular vibration for noninvasive, high-efficiency DNA transfection. *Mol Ther*, 9(4), 607-16 (2004)
DOI: 10.1016/j.ymthe.2004.01.017

48. Z. ur Rehman, D. Hoekstra and I. S. Zuhorn: Mechanism of polyplex- and lipoplex-mediated delivery of nucleic acids: real-time visualization of transient membrane destabilization without endosomal lysis. *ACS Nano*, 7(5), 3767-77 (2013)
DOI: 10.1021/nn3049494
49. Y. L. Chiu and T. M. Rana: siRNA function in RNAi: a chemical modification analysis. *RNA*, 9(9), 1034-48 (2003)
DOI: 10.1261/rna.5103703
50. M. A. Campbell and J. Wengel: Locked vs. unlocked nucleic acids (LNA vs. UNA): contrasting structures work towards common therapeutic goals. *Chem Soc Rev*, 40(12), 5680-9 (2011)
DOI: 10.1039/c1cs15048k
51. H. Peacock, A. Kannan, P. A. Beal and C. J. Burrows: Chemical modification of siRNA bases to probe and enhance RNA interference. *J Org Chem*, 76(18), 7295-300 (2011)
DOI: 10.1021/jo2012225
52. M. Warminski, P. J. Sikorski, J. Kowalska and J. Jemielity: Applications of Phosphate Modification and Labeling to Study (m)RNA Caps. *Top Curr Chem (Cham)*, 375(1), 16 (2017)
DOI: 10.1007/s41061-017-0106-y
53. B. Urban-Klein, S. Werth, S. Abuharbeid, F. Czubayko and A. Aigner: RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA *in vivo*. *Gene Ther*, 12(5), 461-6 (2005)
DOI: 10.1038/sj.gt.3302425
54. J. Soutschek, A. Akinc, B. Bramlage, K. Charisse, R. Constien, M. Donoghue, S. Elbashir, A. Geick, P. Hadwiger, J. Harborth, M. John, V. Kesavan, G. Lavigne, R. K. Pandey, T. Racie, K. G. Rajeev, I. Rohl, I. Toudjarska, G. Wang, S. Wuschko, D. Bumcrot, V. Koteliansky, S. Limmer, M. Manoharan and H. P. Vornlocher: Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. *Nature*, 432(7014), 173-8 (2004)
DOI: 10.1038/nature03121
55. D. M. Copolovici, K. Langel, E. Eriste and U. Langel: Cell-penetrating peptides: design, synthesis, and applications. *ACS Nano*, 8(3), 1972-94 (2014)
DOI: 10.1021/nn4057269
56. Z. Guo, H. Peng, J. Kang and D. Sun: Cell-penetrating peptides: Possible transduction mechanisms and therapeutic applications. *Biomed Rep*, 4(5), 528-534 (2016)
DOI: 10.3892/br.2016.639
57. N. Shajari, B. Mansoori, S. Davudian, A. Mohammadi and B. Baradaran: Overcoming the Challenges of siRNA Delivery: Nanoparticle Strategies. *Curr Drug Deliv*, 14(1), 36-46 (2017)
DOI: 10.2174/1567201813666160816105408
58. J. Halder, A. A. Kamat, C. N. Landen, Jr., L. Y. Han, S. K. Lutgendorf, Y. G. Lin, W. M. Merritt, N. B. Jennings, A. Chavez-Reyes, R. L. Coleman, D. M. Gershenson, R. Schmandt, S. W. Cole, G. Lopez-Berestein and A. K. Sood: Focal adhesion kinase targeting using *in vivo* short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. *Clin Cancer Res*, 12(16), 4916-24 (2006)
DOI: 10.1158/1078-0432.CCR-06-0021
59. M. Saffari, H. R. Moghimi and C. R. Dass: Barriers to liposomal gene delivery: from application site to the target. *Iran J Pharm Res*, 15(Suppl), 3-17 (2016)
60. L. Zhu and R. I. Mahato: Lipid and polymeric carrier-mediated nucleic acid delivery. *Expert Opin Drug Deliv*, 7(10), 1209-26 (2010)
DOI: 10.1517/17425247.2010.513969
61. M.-G. K. Gayong Shim, Joo Yeon Park, Yu-Kyoung Oh: Application of cationic liposomes for delivery of nucleic acids. *Asian Journal of Pharmaceutical Sciences*, 8, 78-80 (2013)
DOI: 10.1016/j.ajps.2013.07.009

62. A. Bajaj, S. K. Mishra, P. Kondaiah and S. Bhattacharya: Effect of the headgroup variation on the gene transfer properties of cholesterol based cationic lipids possessing ether linkage. *Biochim Biophys Acta*, 1778(5), 1222-36 (2008)
DOI: 10.1016/j.bbamem.2007.12.010
63. O. Paecharoenchai, N. Niyomtham, A. Apirakaramwong, T. Ngawhirunpat, T. Rojanarata, B. E. Yingyongnarongkul and P. Opanasopit: Structure relationship of cationic lipids on gene transfection mediated by cationic liposomes. *AAPS PharmSciTech*, 13(4), 1302-8 (2012)
DOI: 10.1208/s12249-012-9857-5
64. D. Liu, Y. K. Song: Cationic liposome-mediated transfection *in vivo*. *Gene Therapy and Molecular Biology* 2, 59-68 (1998)
65. N. S. Templeton, D. D. Lasic, P. M. Frederik, H. H. Strey, D. D. Roberts and G. N. Pavlakis: Improved DNA: liposome complexes for increased systemic delivery and gene expression. *Nat Biotechnol*, 15(7), 647-52 (1997)
DOI: 10.1038/nbt0797-647
66. M. Ramamoorth and A. Narvekar: Non viral vectors in gene therapy- an overview. *J Clin Diagn Res*, 9(1), GE01-6 (2015)
DOI: 10.7860/JCDR/2015/10443.5394
67. K. Tatiparti, S. Sau, S. K. Kashaw and A. K. Iyer: siRNA Delivery Strategies: A Comprehensive Review of Recent Developments. *Nanomaterials (Basel)*, 7(4) (2017)
DOI: 10.3390/nano7040077
68. H. Yin, R. L. Kanasty, A. A. Eltoukhy, A. J. Vegas, J. R. Dorkin and D. G. Anderson: Non-viral vectors for gene-based therapy. *Nat Rev Genet*, 15(8), 541-55 (2014)
DOI: 10.1038/nrg3763
69. S. Biswas and V. P. Torchilin: Dendrimers for siRNA Delivery. *Pharmaceuticals (Basel)*, 6(2), 161-83 (2013)
DOI: 10.3390/ph6020161
70. H. Liu, H. Chang, J. Lv, C. Jiang, Z. Li, F. Wang, H. Wang, M. Wang, C. Liu, X. Wang, N. Shao, B. He, W. Shen, Q. Zhang and Y. Cheng: Screening of efficient siRNA carriers in a library of surface-engineered dendrimers. *Sci Rep*, 6, 25069 (2016)
DOI: 10.1038/srep25069
71. L. B. J. Dongmei Cun, Hanne Mørck Nielsen, Moein Moghimi, and Camilla Foged: Polymeric Nanocarriers for siRNA Delivery: Challenges and Future Prospects. *Journal of Biomedical Nanotechnology*, 4, 1-18 (2008)
DOI: 10.1166/jbn.2008.328
72. F. M. van de Water, O. C. Boerman, A. C. Wouterse, J. G. Peters, F. G. Russel and R. Masereeuw: Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. *Drug Metab Dispos*, 34(8), 1393-7 (2006)
DOI: 10.1124/dmd.106.009555
73. M. Neu, D. Fischer and T. Kissel: Recent advances in rational gene transfer vector design based on poly(ethylene imine) and its derivatives. *J Gene Med*, 7(8), 992-1009 (2005)
DOI: 10.1002/jgm.773
74. L. Aagaard and J. J. Rossi: RNAi therapeutics: principles, prospects and challenges. *Adv Drug Deliv Rev*, 59(2-3), 75-86 (2007)
DOI: 10.1016/j.addr.2007.03.005
75. D. Fischer, Y. Li, B. Ahlemeyer, J. Krieglstein and T. Kissel: *In vitro* cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. *Biomaterials*, 24(7), 1121-31 (2003)
DOI: 10.1016/S0142-9612(02)00445-3
76. S. H. Kim, J. H. Jeong, S. H. Lee, S. W. Kim and T. G. Park: PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. *J Control Release*, 116(2), 123-9 (2006)
DOI: 10.1016/j.jconrel.2006.05.023
77. H. K. Makadia and S. J. Siegel: Poly Lactic-co-Glycolic Acid (PLGA) as

- Biodegradable Controlled Drug Delivery Carrier. *Polymers (Basel)*, 3(3), 1377-1397 (2011)
DOI: 10.3390/polym3031377
78. H. S. M. Ajioka, C. Higuchi, T. Kashima: Aliphatic polyesters and their copolymers synthesized through direct condensation polymerization. *Polymer Degradation and Stability*, 39, 137-143 (1998)
DOI: 10.1016/S0141-3910(97)00165-1
 79. K. Avgoustakis: Polylactic-co-Glycolic Acid (PLGA). In: *Encyclopedia of Biomedical Polymers and Polymeric Biomaterials*. Ed G. L. B. Gary E. Wnek. (2008)
 80. T. K. Gurpreet Singh, Ravinder Kaur, Anudeep Kaur: Recent biomedical applications and patents on biodegradable polymer-PLGA. *International Journal of Pharmacology and Pharmaceutical Sciences* 1(2), 30-42 (2014)
 81. M. Bouyer, R. Guillot, J. Lavaud, C. Plettinx, C. Olivier, V. Curry, J. Boutonnat, J. L. Coll, F. Peyrin, V. Jossierand, G. Bettega and C. Picart: Surface delivery of tunable doses of BMP-2 from an adaptable polymeric scaffold induces volumetric bone regeneration. *Biomaterials*, 104, 168-81 (2016)
DOI: 10.1016/j.biomaterials.2016.06.001
 82. T. M. De Witte, L. E. Fratila-Apachitei, A. A. Zadpoor and N. A. Peppas: Bone tissue engineering via growth factor delivery: from scaffolds to complex matrices. *Regen Biomater*, 5(4), 197-211 (2018)
DOI: 10.1093/rb/rby013
 83. C. M. Hwang, A. Khademhosseini, Y. Park, K. Sun and S. H. Lee: Microfluidic chip-based fabrication of PLGA microfiber scaffolds for tissue engineering. *Langmuir*, 24(13), 6845-51 (2008)
DOI: 10.1021/la800253b
 84. D. H. Kempen, L. Lu, A. Heijink, T. E. Hefferan, L. B. Creemers, A. Maran, M. J. Yaszemski and W. J. Dhert: Effect of local sequential VEGF and BMP-2 delivery on ectopic and orthotopic bone regeneration. *Biomaterials*, 30(14), 2816-25 (2009)
DOI: 10.1016/j.biomaterials.2009.01.031
 85. T. H. Kim, Y. P. Yun, Y. E. Park, S. H. Lee, W. Yong, J. Kundu, J. W. Jung, J. H. Shim, D. W. Cho, S. E. Kim and H. R. Song: *In vitro* and *in vivo* evaluation of bone formation using solid freeform fabrication-based bone morphogenic protein-2 releasing PCL/PLGA scaffolds. *Biomed Mater*, 9(2), 025008 (2014)
DOI: 10.1088/1748-6041/9/2/025008
 86. I. Ortega-Oller, M. Padijal-Molina, P. Galindo-Moreno, F. O'Valle, A. B. Jodar-Reyes and J. M. Peula-Garcia: Bone Regeneration from PLGA Micro-Nanoparticles. *Biomed Res Int*, 2015, 415289 (2015)
DOI: 10.1155/2015/415289
 87. W. J. Zhang, W. Liu, L. Cui and Y. Cao: Tissue engineering of blood vessel. *J Cell Mol Med*, 11(5), 945-57 (2007)
DOI: 10.1111/j.1582-4934.2007.00099.x
 88. J. M. Lu, X. Wang, C. Marin-Muller, H. Wang, P. H. Lin, Q. Yao and C. Chen: Current advances in research and clinical applications of PLGA-based nanotechnology. *Expert Rev Mol Diagn*, 9(4), 325-41 (2009)
DOI: 10.1586/erm.09.15
 89. N. Iverson, N. Plourde, E. Chnari, G. B. Nackman and P. V. Moghe: Convergence of nanotechnology and cardiovascular medicine : progress and emerging prospects. *BioDrugs*, 22(1), 1-10 (2008)
DOI: 10.2165/00063030-200822010-00001
 90. M. A. Wheatley, F. Forsberg, K. Oum, R. Ro and D. El-Sherif: Comparison of *in vitro* and *in vivo* acoustic response of a novel 50:50 PLGA contrast agent. *Ultrasonics*, 44(4), 360-7 (2006)
DOI: 10.1016/j.ultras.2006.04.003
 91. U. S. Toti, B. R. Guru, M. Hali, C. M. McPharlin, S. M. Wykes, J. Panyam and J. A. Whittum-Hudson: Targeted delivery of antibiotics to intracellular chlamydial

- infections using PLGA nanoparticles. *Biomaterials*, 32(27), 6606-13 (2011)
DOI: 10.1016/j.biomaterials.2011.05.038
92. J. K. Vasir and V. Labhasetwar: Biodegradable nanoparticles for cytosolic delivery of therapeutics. *Adv Drug Deliv Rev*, 59(8), 718-28 (2007)
DOI: 10.1016/j.addr.2007.06.003
 93. S. K. Sahoo and V. Labhasetwar: Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. *Mol Pharm*, 2(5), 373-83 (2005)
DOI: 10.1021/mp050032z
 94. E. J. Benjamin, S. S. Virani, C. W. Callaway, A. M. Chamberlain, A. R. Chang, S. Cheng, S. E. Chiuve, M. Cushman, F. N. Delling, R. Deo, S. D. de Ferranti, J. F. Ferguson, M. Fornage, C. Gillespie, C. R. Isasi, M. C. Jimenez, L. C. Jordan, S. E. Judd, D. Lackland, J. H. Lichtman, L. Lisabeth, S. Liu, C. T. Longenecker, P. L. Lutsey, J. S. Mackey, D. B. Matchar, K. Matsushita, M. E. Mussolino, K. Nasir, M. O'Flaherty, L. P. Palaniappan, A. Pandey, D. K. Pandey, M. J. Reeves, M. D. Ritchey, C. J. Rodriguez, G. A. Roth, W. D. Rosamond, U. K. A. Sampson, G. M. Satou, S. H. Shah, N. L. Spartano, D. L. Tirschwell, C. W. Tsao, J. H. Voeks, J. Z. Willey, J. T. Wilkins, J. H. Wu, H. M. Alger, S. S. Wong, P. Muntner, E. American Heart Association Council on, C. Prevention Statistics and S. Stroke Statistics: Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. *Circulation*, 137(12), e67-e492 (2018)
DOI: 10.1161/CIR.0000000000000558
 95. R. A. Byrne, M. Joner and A. Kastrati: Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Gruntzig Lecture ESC 2014. *Eur Heart J*, 36(47), 3320-31 (2015)
DOI: 10.1093/eurheartj/ehv511
 96. X. F. Qiu, N. G. Dong, Z. Q. Sun, P. Hu, W. Su and J. W. Shi: Controlled release of siRNA nanoparticles loaded in a novel external stent prepared by emulsion electrospinning attenuates neointima hyperplasia in vein grafts. *Zhonghua Yi Xue Za Zhi*, 89(41), 2938-42 (2009)
DOI:10.3760/cmaj.issn.0376-2491.2009.41.015
 97. O. Koenig, D. Zengerle, N. Perle, S. Hossfeld, B. Neumann, A. Behring, M. Avci-Adali, T. Walker, C. Schlensak, H. P. Wendel and A. Nolte: RNA-Eluting Surfaces for the Modulation of Gene Expression as A Novel Stent Concept. *Pharmaceuticals (Basel)*, 10(1) (2017)
DOI: 10.3390/ph10010023
 98. H. Cohen-Sacks, Y. Najajreh, V. Tchaikovski, G. Gao, V. Elazer, R. Dahan, I. Gati, M. Kanaan, J. Waltenberger and G. Golomb: Novel PDGFbetaR antisense encapsulated in polymeric nanospheres for the treatment of restenosis. *Gene Ther*, 9(23), 1607-16 (2002)
DOI: 10.1038/sj.gt.3301830
 99. Y. Zhao, H. Gao, J. He, C. Jiang, J. Lu, W. Zhang, H. Yang and J. Liu: Co-delivery of LOX-1 siRNA and statin to endothelial cells and macrophages in the atherosclerotic lesions by a dual-targeting core-shell nanoplatfrom: A dual cell therapy to regress plaques. *J Control Release*, 283, 241-260 (2018)
DOI: 10.1016/j.jconrel.2018.05.041
 100. R. L. Siegel, K. D. Miller and A. Jemal: Cancer statistics, 2018. *CA Cancer J Clin*, 68(1), 7-30 (2018)
DOI: 10.3322/caac.21442
 101. A. Singh, P. Trivedi, N. K. Jain: Advances in siRNAi delivery in cancer therapy. *Artif Cells Nanomed Biotechnol*, 46(2), 274-283 (2018)
DOI: 10.1080/21691401.2017.1307210
 102. K. A. Woodrow, Y. Cu, C. J. Booth, J. K. Saucier-Sawyer, M. J. Wood, W. M. Saltzman: Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. *Nat Mater*, 8(6), 526-533 (2009)
DOI: 10.1038/nmat2444

103. C. Stigliano, S. Aryal, M. D. De Tullio, G. P. Nichhia, G. Pascazio, M. Svelto, P. Decuzzi: siRNA-chitosan complexes in poly(lactic-co-glycolic acid) nanoparticles for the silencing of aquaporin-1 in cancer cells. *Mol Pharm* 10(8), 3186-3194 (2013)
DOI: 10.1021/mp400224u
104. A. K. Kundu, S. V. Iyer, S. Chandra, A. S. Adhikari, T. Iwakuma and T. K. Mandal: Novel siRNA formulation to effectively knockdown mutant p53 in osteosarcoma. *PLoS One*, 12(6), e0179168 (2017)
DOI: 10.1371/journal.pone.0179168
105. B. Mansoori, A. Mohammadi, S. Davudian, S. Shirjang and B. Baradaran: The Different Mechanisms of Cancer Drug Resistance: A Brief Review. *Adv Pharm Bull*, 7(3), 339-348 (2017)
DOI: 10.15171/apb.2017.041
106. A. Levy, K. Alhazzani, P. Dondapati, A. Alaseem, K. Cheema, K. Thallapureddy, P. Kaur, S. Alobid and A. Rathinavelu: Focal Adhesion Kinase in Ovarian Cancer: A Potential Therapeutic Target for Platinum and Taxane-Resistant Tumors. *Curr Cancer Drug Targets* (2018)
DOI: 10.2174/1568009618666180706165222
107. Y. Byeon, J. W. Lee, W. S. Choi, J. E. Won, G. H. Kim, M. G. Kim, T. I. Wi, J. M. Lee, T. H. Kang, I. D. Jung, Y. J. Cho, H. J. Ahn, B. C. Shin, Y. J. Lee, A. K. Sood, H. D. Han and Y. M. Park: CD44-targeted PLGA nanoparticles incorporating paclitaxel and FAK siRNA overcome chemoresistance in epithelial ovarian cancer. *Cancer Res* (2018)
DOI: 10.1158/0008-5472.CAN-17-3871
108. C. Risnayanti, Y. S. Jang, J. Lee and H. J. Ahn: PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer. *Sci Rep*, 8(1), 7498 (2018)
DOI: 10.1038/s41598-018-25930-7
109. M. Wu, J. Li, X. Lin, Z. Wei, D. Zhang, B. Zhao, X. Liu and J. Liu: Reduction/photo dual-responsive polymeric prodrug nanoparticles for programmed siRNA and doxorubicin delivery. *Biomater Sci*, 6(6), 1457-1468 (2018)
DOI: 10.1039/c8bm00226f
110. B. C. te Boekhorst, L. B. Jensen, S. Colombo, A. K. Varkouhi, R. M. Schiffelers, T. Lammers, G. Storm, H. M. Nielsen, G. J. Strijkers, C. Foged and K. Nicolay: MRI-assessed therapeutic effects of locally administered PLGA nanoparticles loaded with anti-inflammatory siRNA in a murine arthritis model. *J Control Release*, 161(3), 772-80 (2012)
DOI: 10.1016/j.jconrel.2012.05.004
111. C. Kelly, A. B. Yadav, C. Lawlor, K. Nolan, J. O'Dwyer, C. M. Greene, N. G. McElvaney, N. Sivadas, J. M. Ramsey and S. A. Cryan: Therapeutic aerosol bioengineering of siRNA for the treatment of inflammatory lung disease by TNFalpha gene silencing in macrophages. *Mol Pharm*, 11(11), 4270-9 (2014)
DOI: 10.1021/mp500473d
112. A. Frede, B. Neuhaus, R. Klopffleisch, C. Walker, J. Buer, W. Muller, M. Epple and A. M. Westendorf: Colonic gene silencing using siRNA-loaded calcium phosphate/PLGA nanoparticles ameliorates intestinal inflammation *in vivo*. *J Control Release*, 222, 86-96 (2016)
DOI: 10.1016/j.jconrel.2015.12.021
113. A. M. Aldayel, Y. W. Naguib, H. L. O'Mary, X. Li, M. Niu, T. B. Ruwona and Z. Cui: Acid-Sensitive Sheddable PEGylated PLGA Nanoparticles Increase the Delivery of TNF-alpha siRNA in Chronic Inflammation Sites. *Mol Ther Nucleic Acids*, 5(7), e340 (2016)
DOI: 10.1038/mtna.2016.39
114. M. J. Gomes, C. Fernandes, S. Martins, F. Borges and B. Sarmiento: Tailoring Lipid and Polymeric Nanoparticles as siRNA Carriers towards the Blood-Brain Barrier - from Targeting to Safe Administration. *J Neuroimmune Pharmacol*, 12(1), 107-119 (2017)
DOI: 10.1007/s11481-016-9685-6

115. C. Chen, H. Mei, W. Shi, J. Deng, B. Zhang, T. Guo, H. Wang and Y. Hu: EGFP-EGF1-conjugated PLGA nanoparticles for targeted delivery of siRNA into injured brain microvascular endothelial cells for efficient RNA interference. *PLoS One*, 8(4), e60860 (2013)
DOI: 10.1371/journal.pone.0060860
116. X. Liu, G. Wang, Z. You, P. Qian, H. Chen, Y. Dou, Z. Wei, Y. Chen, C. Mao and J. Zhang: Inhibition of hypoxia-induced proliferation of pulmonary arterial smooth muscle cells by a mTOR siRNA-loaded cyclodextrin nanovector. *Biomaterials*, 35(14), 4401-16 (2014)
DOI: 10.1016/j.biomaterials.2014.02.009

Abbreviations: apoB: apolipoprotein B, Ago2: Argonaute 2, CHS: chalcone synthase, CPP: cell-penetrating peptides, dsRNA: double-stranded RNA, DOX: doxorubicin, FAK: focal adhesion kinase, ICAM-1: intracellular adhesion molecule 1, LNA: locked nucleic acids, mRNA: messenger RNA, miRNA: micro RNA, NPs: nanoparticles, piRNA: PIWI-interacting RNA, pre-miRNA: precursor-microRNA, pri-miRNA: primary-microRNA, PTGS: post-transcriptional gene silencing, RISC: RNA-induced silencing, RNAi: RNA interference, siRNA: small interfering RNA, ssRNA: single-stranded RNA, TRBP: TAR-RNA binding protein, PAMAM: polyamidoamine, PEG: polyethylene glycol, PEI: complex polyethyleneimine, P-gp: P-glycoprotein, PLGA: poly(lactide-co-glycolide), PLL: poly-L-lysine, PVA: poly (vinyl alcohol), TGS: transcriptional gene silencing, UNA: unlocked nucleic acids, TNF- α : Tumor necrosis factor- α , VEGF: vascular endothelial growth factor.

Key Words: RNA interference, siRNA, gene therapy, Non-Viral Delivery, PLGA nanoparticles, Review

Send correspondence to: Rita Maalouf, Department of Sciences, Faculty of Natural and Applied Sciences, Notre Dame University - Louaize, Zouk Mosbeh, Lebanon P.O.Box: 72, Zouk Mikael, Tel: 961-9 208745, Fax: 961-9 218771, E-mail: rita.maalouf@ndu.edu.lb